Original Article

Analysis of Clinical and Laboratory Findings of Secondary Amyloidosis

Volume 27 · Issue 3 Publish Date: January 29, 2019
Full Text PDF
Kadir Gökhan ATILGAN
Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Nefroloji Bölümü, Ankara, Türkiye
Ali Rıza ODABAŞ
Medeniyet Üniversitesi Tıp Fakültesi, Nefroloji Bilim Dalı, İstanbul, Türkiye
Fatih DEDE
Numune Eğitim ve Araştırma Hastanesi, Nefroloji Bölümü, Ankara, Türkiye
Mehmet Deniz AYLI
Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Nefroloji Bölümü, Ankara, Türkiye
ATILGAN, K. G., ODABAŞ, A. R., DEDE, F., & AYLI, M. D. (2019). Analysis of Clinical and Laboratory Findings of Secondary Amyloidosis. Turkish Journal of Nephrology, 27(3), 267–271. Retrieved from https://www.turkjnephrol.org/index.php/pub/article/view/1250
Full Text Full Text PDF

Abstract

OBJECTIVE: Our aim was to investigate the clinical and laboratory findings of patients with AAamyloidosis.

MATERIAL and METHODS: Fifty-nine patients with AA-amyloidosis were included in this study. The patients were divided into 2 groups. Group-1 consisted of 23 patients with AA-amyloidosis due to familial mediterranean fever (FMF) and Group-2 consisted of 36 patients with AA-amyloidosis due to etiologies other than FMF. The laboratory and clinical characteristics of all patients were compared between groups.

RESULTS: Of the patients, edema was found in 47 (79.6%), hepatomegaly in 8 (13%), splenomegaly in 9 (14.7%), and hypertension in 21 (35.6%). The median age, systolic/ diastolic blood pressure, serum albumin, total cholesterol, creatinine, and proteinuria values of Group-1 and Group-2 were 29 (16- 73) and 50 (16-76) years (p: 0.001)., 135±12.4 / 73.1±9.2 and 133±13.1 / 72.4±8.9 mmHg (p>0.05), 3.33±0.86 and 2.60±0.92 mg/dl (p:0.04), 238.08±115.68 and 227.77±82.52 mg/dl (p>0.05), 2.51±2.74 and 3.81±3.31 mg/dl (p>0.05), 4.35±3.53 and 5.58±5.10 g/day (p>0.05) respectively. Renal replacement therapy (RRT) was performed in 5 patients in Group-1 and 11 patients in Group-2.

CONCLUSION: The most common cause of AA-amyloidosis in our study was FMF, followed by bronchiectasis and chronic obstructive pulmonary disease. Patients with amyloidosis due to FMF were younger than the patients with amyloidosis due to other etiologies. The need for RRT was similar between the groups.

Similar Articles

Article Info
Published In
Journal Turkish Journal of Nephrology
Volume / Issue Volume 27 · Issue 3
Pages 267-271
History
Published Online January 29, 2019
Copyright
Affiliations
Kadir Gökhan ATILGAN
Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Nefroloji Bölümü, Ankara, Türkiye
Ali Rıza ODABAŞ
Medeniyet Üniversitesi Tıp Fakültesi, Nefroloji Bilim Dalı, İstanbul, Türkiye
Fatih DEDE
Numune Eğitim ve Araştırma Hastanesi, Nefroloji Bölümü, Ankara, Türkiye
Mehmet Deniz AYLI
Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Nefroloji Bölümü, Ankara, Türkiye
Cite this Article
ATILGAN, K. G., ODABAŞ, A. R., DEDE, F., & AYLI, M. D. (2019). Analysis of Clinical and Laboratory Findings of Secondary Amyloidosis. Turkish Journal of Nephrology, 27(3), 267–271. Retrieved from https://www.turkjnephrol.org/index.php/pub/article/view/1250
Outlines